A new treatment approach for colorectal cancer using specialized nanoparticles.
A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy
This study is testing a new treatment for colorectal cancer that combines special tiny particles with cancer-fighting drugs to help your immune system work better against the cancer, especially if other treatments haven't worked for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11056724 on NIH RePORTER |
What this research studies
This research focuses on developing a novel liposomal nanotherapeutic platform designed to enhance the effectiveness of immunotherapy for colorectal cancer. By conjugating anticancer agents to phospholipids, the researchers aim to improve the delivery and efficacy of chemotherapy while minimizing side effects. The approach seeks to convert tumors from an 'immune-cold' state to an 'immune-hot' state, thereby increasing the response rate to immune checkpoint inhibitors. Patients with colorectal cancer who have not responded to traditional therapies may find this innovative treatment beneficial.
Who could benefit from this research
Good fit: Ideal candidates for this research are colorectal cancer patients, particularly those who have not responded to existing therapies.
Not a fit: Patients with colorectal cancer who have mismatch-repair-deficient or microsatellite instability-high tumors may not benefit as they are already eligible for existing immunotherapy options.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for colorectal cancer patients who currently have limited options.
How similar studies have performed: While the use of nanotherapeutics in cancer treatment is a growing field, this specific approach is innovative and has not been widely tested in colorectal cancer.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Lu, Jianqin — University of Arizona
- Study coordinator: Lu, Jianqin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.